Here is your NEWS-Line for Pharmacists eNewsletter. For the latest news, jobs, education and blogs, bookmark our news page and job board or to take us everywhere with you, save this link to your phone. Also, enjoy the latest issue of NEWS-Line magazine, always free.
Why COVID-19 Infection Curves Behave so Unexpectedly
With the first COVID-19 epidemic peak behind them, many countries explained the decrease of infection numbers through non-pharmaceutical interventions. Phrases like "social distancing" and "flatten the curve" have become part of common vocabulary. Yet some explanations fell short: How could one explain the linear rise of infection curves, which many countries display after the first peak, in contrast to the S-shaped curves, expected from epidemiological models?
In a new paper published in PNAS (Proceedings of the National Academy of Sciences of the United States of America), scientists at the Complexity Science Hub Vienna (CSH) and the Medical University of Vienna are the first ones to offer an explanation for the linear growth of the infection curve.
"At the beginning of the pandemic, COVID-19 infection curves showed the expected exponential growth," says Stefan Thurner, CSH president
Read Full Article
Enzyme May Be Key to Unlocking Treatment for Cancer, Diabetes, UArizona Health Sciences Researcher Says
Preliminary studies conducted by James Galligan, PhD, an assistant professor at the University of Arizona College of Pharmacy, suggest the enzyme glyoxalase II (GLO2) is a strong candidate for drug developers to consider as a potential treatment for breast cancer and diabetes.
The enzyme plays a key role in the rate of cell growth and a therapy targeting this function may help to control the development and spread of certain diseases. Dr. Galligan, who specializes in cellular metabolism and how diseases originate, recently received a five-year $1.8 million research grant from the National Institutes of Health (NIH) to continue his investigation into this possibility.
The glyoxalase system is a set of biological compounds that accelerate chemical reactions in the body and help protect against cellular damage. The system is made up of two enzymes, glyoxalase I and glyoxalase II, both o
Read Full Article
Studies by AHN Neurologists Improve Understanding of Stroke Therapy Risks in Patients with Chronic Health Conditions
Intravenous thrombolysis may put stroke patients with chronic kidney disease (CKD) at a higher risk for intracranial bleeding and mortality, according to a recent study published in the journal Neurology by researchers at the Allegheny Health Network (AHN) Neuroscience Institute. The study, “Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis,” surveyed various studies published across different countries and assessed the association of CKD among more than 60,000 acute ischemic stroke patients undergoing IV thrombolytic therapy.
According to the CDC, stroke kills about 140,000 Americans each year, accounting for approximately one out of every 20 deaths. Nearly 90 percent of strokes are classified as acute ischemic strokes which take place when a blood clot or narrowed artery obstructs blood flow to the brain. Within minutes, the lac
Read Full Article
The Compounding Quality Coalition Commends the FDA for its Continued Commitment of Protecting Public Health
The Compounding Quality Coalition (CQC), comprised of a diverse, multi-sector group of stakeholders from public health, manufacturing, outsourcing facilities, and the pharmacy community, issued a public comment to Food and Drug Administration (FDA) notice entitled "Agency Information Collection Activities; Proposed Collection; Comment Request; Obtaining Information To Understand Challenges and Opportunities Encountered by Compounding Outsourcing Facilities."
The CQC commends the FDA for its continued commitment of protecting public health by assuring access to safe and efficacious medicines are timely available to patients. The coalition appreciates the Agency's interest in developing a comprehensive understanding of the outsourcing compounding sector to address special patient and hospital needs that are unmet by commercially available products that have been approved by the FDA. The C